In 2015, Loncar Investments, which is the index provider to a cancer immunotherapy themed exchange-traded fund (ETF) that is traded on Nasdaq, entered into an exclusive charitable partnership with the Cancer Research Institute whereby Loncar will use royalties it receives to make regular contributions to CRI.

*Immunotherapy results may vary from patient to patient.